Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 AbbVie: A High-Yielder That Can Flood You With Cash
2 Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion
3 Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
4 AbbVie in Alzheimer's disease: how likely are future trials?
5 AbbVie Inc. stock falls Wednesday, underperforms market
6 AbbVie's Vuity snags FDA approval as first eye drop for presbyopia, with rival Eyenovia close behind
7 AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025
8 AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
9 AbbVie's Parkinson's pump hits goal in phase 3, setting stage for approval filings
10 AbbVie: Biotech Favorite With A Hitch
11 Worldwide Botulinum Toxin Industry to 2030
12 AbbVie, Exxon Mobil, and Other Companies That Raised Their Dividends Last Week
13 Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting
14 AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU
15 RegenxBio's deal with AbbVie just closed. It could mean more than $1B for the local company.
16 AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
17 AbbVie Announces First Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia in Quebec
18 AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
19 Digital Medicine Society teams up with AbbVie, Novartis, Pfizer, UCB, Janssen on digital endpoints initiative
20 The Zacks Analyst Blog Highlights: Tesla, Comcast, AbbVie, Boeing, China Petroleum & Chemical and Advanced Micro Devices
21 AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021
22 AbbVie-backed Nitrome adds BMS as investor in $45M series A, snags Nurix CBO as CEO and rebrands to Nitrase
23 Johnson & Johnson, AbbVie, Teva and Endo score industry's first opioid trial win
24 ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again
25 AbbVie Inc. stock rises Friday, still underperforms market
26 Migraine marketing wars? AbbVie, Biohaven, Eli Lilly, Amgen lead push for attention in newly competitive space
27 Global Antibody Drugs Market (2021 to 2026)
28 AbbVie's Rinvoq to provide personalized treatment for atopic dermatitis patients
29 Brand Drugs Market to Eyewitness Massive Growth by 2026 | Novartis, AbbVie, Eli Lilly, Teva – UK Parents Lounge
30 Outlook on the Trispecific Antibody Global Market to 2028
31 Regeneron and Novo Nordisk hold tight at the top spots on October list of biggest TV ad spenders
32 Pharmaceutical company AbbVie inflated prices for two major drugs, House Oversight report says
33 AbbVie Stock Dropped After FDA Warning. Analysts Say Selloff Is Overblown.
34 Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting
35 House of Representatives Holds Hearing Focused on AbbVie Business Practices
36 Should You Buy AbbVie Stock After The Recent 7% Fall?
37 Korean biosimilars threaten originals in global market < Bio < 기사본문
38 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
39 4 Top Dividend Stocks I'd Buy If I Were About to Retire
40 Here’s Why AbbVie Stock Will Likely See Higher Levels
41 AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit
42 AbbVie's Imbruvica patent win sets up solid growth path after Humira's decline: analyst
43 Even AbbVie CEO can't confirm Rinvoq's sales as FDA mulls JAK label
44 Exclusive: AbbVie in talks to sell $5 billion women's drugs portfolio
45 AbbVie exec details upbeat plan for Rinvoq, Skyrizi as Humira copycats near: analyst
46 Alvotech scores in AbbVie trade secrets case, but the Humira patent fight will stretch into next year
47 AbbVie Dips as Stalled FDA Action on Rinvoq Worries Investors
48 Why AbbVie Stock Sank in September
49 FDA Approves AbbVie's Qulipta
50 Takeda breached its contract with AbbVie by failing to supply prostate cancer drug Lupron, court rules
51 AbbVie CEO summoned to Congress—again—to answer questions on Humira pricing, patenting
52 Regenxbio Stock Soars on AbbVie Eye Therapy Partnership
53 AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
54 Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
55 U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
56 AbbVie Could Be a Good Defensive Play
57 AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
58 AbbVie, J&J units' Imbruvica patents upheld by Delaware court
59 Better Dividend Stock: AbbVie or Pfizer?
60 As AbbVie and Soliton shake hands on a $550M merger, the FTC says 'not so fast'
61 AbbVie, on a Mission, picks Alzheimer's, Parkinson's targets, as partner nabs $20M
62 Should You Buy AbbVie in April?
63 Is AbbVie a Buy Before Its Earnings Report Friday?
64 CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington's intensifying drug-pricing push
65 Pharma giant AbbVie helps fund ads attacking prescription drug bill after hiking prices up to 470%
66 AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts
67 AbbVie Appears Ready To Reverse And Outperform
68 Could These Clinical Results Mean Profit for AbbVie Shareholders?
69 Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson's Disease and Other Related Disorders
70 FTC drops antitrust case against AbbVie, but still decries the company's 'ill-gotten gains'
71 As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement
72 AbbVie's Vraylar turns in mixed results in depression, but pharma decides to file for approval anyway
73 AbbVie: The Humira Situation Remains Scary
74 Breast Implants Market 2021-2028 Size, Share, Growth Factors, Trends, Revenue, Competitive Landscape, Forecast Report by Fortune Business Insights
75 AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?
76 Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors' survey shows
77 What Rinvoq's Positive News Means for AbbVie
78 AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq
79 UPDATED: AbbVie accuses rival of stealing blockbuster 'trade secrets' as clock ticks down on biosimilar assault
80 AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq
81 Recon: Abbvie and Calico craft $1B deal; Purdue creditors sign deal to shield Sacklers
82 AbbVie's big Rinvoq ambitions—and the larger JAK class—face even more uncertainty with latest FDA delays
83 AbbVie touts more Rinvoq data in inflammatory spinal arthritis as it awaits key FDA decisions
84 AbbVie Inc.'s (ABBV) CEO Rich Gonzalez Presents at Morgan Stanley Virtual 19th Annual Global Healthcare Conference (Transcript)
85 AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
86 Implant maker AbbVie launches breast cancer campaign to highlight reconstruction options
87 The Sham Litigation Exception after AbbVie
88 Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data
89 AbbVie Vs. Moderna Stock: Which Is The Better Buy?
90 AbbVie Announces Application of Skyrizi to FDA for Treatment of Crohn's Disease
91 Morning Bell With Jim Cramer: Boeing and AbbVie
92 AbbVie's Rinvoq marches toward blockbuster ulcerative colitis nod even as JAK delays drag on
93 This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
94 How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market
95 Alvotech, not content to line up behind other Humira biosims, sues AbbVie over 'wrongful monopoly'
96 Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst
97 AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
98 Abbvie bets on strong Humira rebound
99 AbbVie | 2021 World's Best Workplaces
100 An AbbVie clinical vet heading early oncology jumps ship to build his own team at NK cell-focused biotech